What the headline figures actually show

The published post-market dataset for ChondroFiller covers more than 19,000 treatments since the device entered clinical use in 2013 — and across that entire record, the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025) logs zero serious adverse device effects (SADEs). A serious adverse device effect is defined as an unintended consequence causing organ damage, unplanned hospitalisation, or lasting injury. That tally has remained at zero across more than a decade of continuous post-market surveillance spanning more than 20 European countries and eight joint types, including the knee, hip, ankle, and wrist.

Three further figures from the same report complete the headline picture. The overall device complaint rate — a formal regulatory notification of a product issue, which does not necessarily represent direct clinical harm to a patient — sits at approximately 0.06%, equivalent to fewer than one report per 1,600 treatments. The device-related complication rate across pooled post-market cohort and registry studies is cited as approximately 0%. The most frequently logged device issue is non-gelation, where the liquid collagen scaffold does not polymerise fully inside the defect; this occurs in roughly 0.01% of cases and is classified as a procedural outcome rather than a patient-harm event.

Taken together, these figures represent a safety profile from real-world use at scale — not from a single controlled trial, but from a structured, audited regulatory dataset covering the full breadth of clinical application.

Where this safety data comes from

Behind those figures sits a single primary source: the Clinical Evaluation Report (CER) Version 09, published by Meidrix Biomedicals GmbH on 30 April 2025. Under EU Medical Device Regulation, every CE-certified Class III device — the highest-risk tier — must submit a CER as a mandatory regulatory document. It carries defined legal weight: it is not a marketing brochure but a structured submission reviewed by a notified body as part of the CE certification process. The data it draws on include pooled post-market clinical follow-up (PMCF) studies, prospective cohort records, and real-world registry entries accumulated since ChondroFiller's clinical launch in 2013 — a body of surveillance that has grown continuously across the entire period of the device's use in Europe.

Two limitations matter. First, the CER is manufacturer-sponsored: the aggregate figures have not been independently audited or replicated by a large-scale randomised controlled trial. That does not nullify them — the EU MDR framework imposes structured reporting requirements and independent notified-body oversight — but it does mean the numbers should be read as regulatory evidence rather than independently verified science. Second, the one available independent peer-reviewed study, a 2025 prospective analysis by Matta et al. (PMC12498443), found no significant complication difference between ChondroFiller-treated patients and controls in wrist cartilage repair. Its scope is narrow and its joint type specific, but its direction is consistent with the post-market record.

Taken together, the evidence base is substantial in scale yet carries the provenance caveat that all figures ultimately trace to a single regulatory submission.

Side effects patients commonly report

For most patients, the days immediately following an ultrasound-guided ChondroFiller injection bring a familiar cluster of localised responses: swelling around the treated joint, a temporary flare in pain, and some stiffness. These effects are self-limiting and typically settle within a short period without intervention. A small number of patients have also noted mild crepitus — a faint grating or clicking sensation in the joint — though this has not been associated with adverse clinical outcomes in published case series.

The one meaningful risk that warrants specific attention before treatment is localised hypersensitivity. ChondroFiller is composed of Type I collagen derived from rat (murine) tissue. Patients with a known sensitivity to animal-derived proteins, and particularly to rat-derived collagen, face an absolute contraindication: the scaffold material cannot safely be used. Screening for collagen or animal-protein allergy is therefore a standard part of the pre-treatment assessment. Published clinical studies to date have not reported immunogenic adverse events following ChondroFiller injection — an encouraging signal, though one that sits within the manufacturer-sourced evidence base described in the previous section.

Systemic contraindications — including active malignancy and severe bleeding disorders — are assessed at consultation before any treatment proceeds. These exclusions exist to protect patients for whom the procedure carries disproportionate risk irrespective of the cartilage indication.

Reoperation rates compared with surgical cartilage repair

Published reoperation figures place ChondroFiller in a markedly different range from the surgical cartilage-repair alternatives. Across published cohorts, the reoperation rate for ChondroFiller sits at 3–8%, compared with up to 41% for microfracture and up to 37% for autologous chondrocyte implantation or matrix-associated ACI (ACI/MACI) — both of which are theatre-based surgical procedures. ACI/MACI also carries a reported complication rate of up to 17%, which provides further context when weighing ChondroFiller's approximate 0% figure.

Part of that difference is structural. Microfracture and ACI/MACI require theatre admission, incisions or arthroscopic portals, and in many cases general anaesthesia — each of which introduces procedural risk that simply does not exist in an outpatient, ultrasound-guided injection pathway. ChondroFiller is delivered as an injectable collagen scaffold placed under image guidance in a clinic setting; there are no incisions, no theatre stay, and no anaesthetic recovery period.

Part of the difference also reflects patient selection, and this caveat matters. ChondroFiller is indicated for focal, well-defined cartilage defects — not diffuse joint disease — in patients with healthy surrounding cartilage borders. Surgical techniques are sometimes employed for larger or more complex lesions where an injectable approach would not be appropriate. Comparing reoperation rates across these groups is therefore informative but not a like-for-like evaluation; the figures are best read as contextual benchmarks rather than direct head-to-head results.

What imaging shows about tissue response

MOCART scoring — Magnetic Resonance Observation of Cartilage Repair Tissue — is a standardised MRI grading system used to assess the quality of repair tissue filling a cartilage defect. Scores run from 0 to 100; higher values indicate more complete defect filling and better repair-tissue characteristics. In imaging studies of ChondroFiller, published data report scores rising from approximately 65.3 at four weeks post-treatment to 81.6 at one year — a trajectory that indicates progressive scaffold integration and tissue maturation over that period.

That improvement beyond 80 corresponds to greater than 80% defect filling on imaging — a structural signal that the collagen scaffold is incorporating into the joint environment rather than provoking an adverse tissue response. Post-treatment MRI findings in the same studies describe reduction in bone marrow oedema and visible widening of the joint space: both markers of a settling tissue response consistent with the absence of inflammatory or immunogenic reaction.

These are objective structural observations, not proxy measures derived from symptom questionnaires. They do not confirm full cartilage regeneration — the published evidence base does not support that claim — but they do provide biological plausibility for the safety profile documented in the wider post-market surveillance dataset.

Gaps in the evidence and who the data applies to

Three boundaries define who the safety data actually covers — and understanding each one helps calibrate what the 19,000-treatment record does and does not settle.

Patient selection

The approximately 0% complication rate reflects outcomes in a specific, carefully assessed group: patients with focal Grade III–IV cartilage defects bounded by healthy surrounding tissue at the defect margins. Diffuse osteoarthritis, poor surrounding cartilage quality, active systemic malignancy, severe bleeding disorders, and sensitivity to rat-derived collagen proteins all sit outside the studied population. Extending the headline figures to those presentations is not supported by the published data — a point that earlier sections noted briefly but that bears stating in full here, as it governs almost every number in the article.

UK access and regulatory standing

ChondroFiller holds CE Class III certification under EU Medical Device Regulation — the highest-risk tier, requiring continuous post-market clinical follow-up and periodic regulatory review. That CE mark does not, however, translate to NHS commissioning in England or across the devolved nations. The current UK pathway is private; a formal suitability assessment determines whether a given patient's joint, defect profile, and clinical history fall within the studied indication. The independent literature remains limited in volume compared with more established cartilage-repair procedures, and the evidence base is still accumulating.

What the 19,000-case figure settles is a population-level picture in a well-defined patient group. What it cannot resolve is whether any particular individual belongs in that group — which is precisely what a structured suitability assessment is designed to determine.